The retinal disorder treatment market size has grown rapidly in recent years. It will grow from $11.57 billion in 2023 to $12.74 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The observed growth during the historical period can be attributed to factors such as the introduction of anti-VEGF therapies, an aging population, increased incidence of retinal disorders, improved diagnostic tools for early detection, increased awareness and screening programs, and expanded access to healthcare services.
The retinal disorder treatment market size is expected to see strong growth in the next few years. It will grow to $17.93 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The anticipated growth in the forecast period can be attributed to factors such as patient-centric approaches in retinal healthcare, increasing global healthcare expenditure, a greater focus on combination therapies for retinal disorders, the rise of home-based retinal disorder monitoring, the increasing adoption of implantable devices for retina treatment, and the adoption of regenerative medicine in retina treatment. Major trends expected in the forecast period include advancements in ophthalmic imaging technologies, the development of minimally invasive surgical techniques, the integration of artificial intelligence in diagnostics, advancements in drug delivery technologies, the integration of virtual reality in retinal rehabilitation, collaborations between research institutions and pharmaceutical companies, and the development of gene therapies for genetic retinal diseases.
The anticipated increase in the prevalence of retinal disorders is set to drive the expansion of the retinal disorder treatment market. Retinal diseases encompass medical conditions affecting the retina, the light-sensitive tissue at the back of the eye, and can lead to vision loss or severe visual impairment. Treatments for retinal disorders, including laser therapy, vitrectomy, and retinal implants, play a crucial role in managing and alleviating symptoms. As of January 2023, the International Agency for the Prevention of Blindness reports that age-related macular degeneration (AMD) is projected to account for approximately 5% of global blindness. The prevalence of AMD is expected to impact 288 million individuals by the year 2040. Thus, the rising incidence of retinal disorders is a significant driver for the growth of the retinal disorder treatment market.
The increasing prevalence of diabetes is anticipated to further bolster the growth of the retinal disorder treatment market. Diabetes, characterized by elevated blood glucose levels, can lead to diabetic retinopathy, the most common retinal disorder among individuals with diabetes. Damage to blood vessels in the retina can result in bleeding, fluid leakage, and the development of new blood vessels. Retinal disorder treatments, including laser interventions, are employed to address such complications. As of July 2021, the International Diabetes Federation projects a global diabetic population of 537 million in 2021, rising to 643 million in 2030 and 783 million in 2045. The prevalence of impaired glucose tolerance is estimated to reach 541 million by 2021. The increasing incidence of diabetes is thus a key driver for the growth of the retinal disorder treatment market.
A notable trend gaining traction in the retinal disorder treatment market is the innovation of products by major companies. These innovations are introduced to maintain a competitive edge in the market. For example, in January 2022, F. Hoffmann-La Roche AG, a pharmaceutical company based in Switzerland, received FDA approval for Vabysmo. Vabysmo is a bispecific antibody designed to treat neovascular or wet age-related macular degeneration (AMD) and diabetic macular edema (DME). It represents the first injectable eye medication targeting and inhibiting two disease pathways, Angiopoietin-2 (Ang-2) and Vascular Endothelial Growth Factor-A (VEGF-A), associated with retinal diseases. Clinical trials demonstrated non-inferior vision improvements compared to traditional therapy, with a favorable safety profile.
Major companies in the retinal disorder treatment market are actively developing innovative products, including treatments for geographic atrophy, to expand their customer bases, boost sales, and increase revenue. Geographic atrophy treatments focus on symptom management, disease progression mitigation, and aiding individuals in coping with visual impairment. For instance, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, received FDA approval for IZERVAY. As a novel complement C5 inhibitor, IZERVAY is the sole approved treatment for geographic atrophy (GA) showing a statistically significant reduction (p< 0.01) in the rate of GA progression in two Phase 3 clinical trials. This distinction positions IZERVAY as an effective therapy for GA secondary to age-related macular degeneration (AMD).
In July 2023, Astellas Pharma Inc. acquired Iveric Bio Inc., a biopharmaceutical company based in the United States, for an undisclosed amount. This strategic acquisition is aimed at expanding Astellas' presence in ophthalmology, gaining access to innovative therapies for retinal diseases, and enhancing its position in the market for treating ophthalmologic conditions and vision loss.
Major companies operating in the retinal disorder treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Adverum Biotechnologies Inc., Kodiak Sciences Inc., Acucela Inc., IVERIC bio Inc., Oxurion NV, Graybug Vision Inc., Icon Bioscience Inc., Clearside Biomedical Inc., Aerpio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Ophthotech Corporation, Opthea Limited, PanOptica Inc., ThromboGenics NV.
North America was the largest region in the retinal disorder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinal disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The main types of retinal disorder treatment include macular degeneration, diabetic retinopathy, and others. Macular degeneration, often referred to as age-related macular degeneration (AMD), is a chronic eye condition primarily affecting the macula - the central area of the retina responsible for clear central vision. Treatment options are available in various dosage forms, including gels, eye solutions, capsules, tablets, eye drops, and ointments. These treatments are typically distributed through hospital pharmacies, online pharmacies, and retail pharmacies.
The retinal disorder treatment market research report is one of a series of new reports that provides retinal disorder treatment market statistics, including the retinal disorder treatment industry's global market size, regional shares, competitors with a retinal disorder treatment market share, detailed retinal disorder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinal disorder treatment industry. This retinal disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The retinal disorder treatment market includes revenues earned by entities by providing retinal detachment, laser treatment, genetic treatments, and photodynamic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The retinal disorder treatment market size is expected to see strong growth in the next few years. It will grow to $17.93 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The anticipated growth in the forecast period can be attributed to factors such as patient-centric approaches in retinal healthcare, increasing global healthcare expenditure, a greater focus on combination therapies for retinal disorders, the rise of home-based retinal disorder monitoring, the increasing adoption of implantable devices for retina treatment, and the adoption of regenerative medicine in retina treatment. Major trends expected in the forecast period include advancements in ophthalmic imaging technologies, the development of minimally invasive surgical techniques, the integration of artificial intelligence in diagnostics, advancements in drug delivery technologies, the integration of virtual reality in retinal rehabilitation, collaborations between research institutions and pharmaceutical companies, and the development of gene therapies for genetic retinal diseases.
The anticipated increase in the prevalence of retinal disorders is set to drive the expansion of the retinal disorder treatment market. Retinal diseases encompass medical conditions affecting the retina, the light-sensitive tissue at the back of the eye, and can lead to vision loss or severe visual impairment. Treatments for retinal disorders, including laser therapy, vitrectomy, and retinal implants, play a crucial role in managing and alleviating symptoms. As of January 2023, the International Agency for the Prevention of Blindness reports that age-related macular degeneration (AMD) is projected to account for approximately 5% of global blindness. The prevalence of AMD is expected to impact 288 million individuals by the year 2040. Thus, the rising incidence of retinal disorders is a significant driver for the growth of the retinal disorder treatment market.
The increasing prevalence of diabetes is anticipated to further bolster the growth of the retinal disorder treatment market. Diabetes, characterized by elevated blood glucose levels, can lead to diabetic retinopathy, the most common retinal disorder among individuals with diabetes. Damage to blood vessels in the retina can result in bleeding, fluid leakage, and the development of new blood vessels. Retinal disorder treatments, including laser interventions, are employed to address such complications. As of July 2021, the International Diabetes Federation projects a global diabetic population of 537 million in 2021, rising to 643 million in 2030 and 783 million in 2045. The prevalence of impaired glucose tolerance is estimated to reach 541 million by 2021. The increasing incidence of diabetes is thus a key driver for the growth of the retinal disorder treatment market.
A notable trend gaining traction in the retinal disorder treatment market is the innovation of products by major companies. These innovations are introduced to maintain a competitive edge in the market. For example, in January 2022, F. Hoffmann-La Roche AG, a pharmaceutical company based in Switzerland, received FDA approval for Vabysmo. Vabysmo is a bispecific antibody designed to treat neovascular or wet age-related macular degeneration (AMD) and diabetic macular edema (DME). It represents the first injectable eye medication targeting and inhibiting two disease pathways, Angiopoietin-2 (Ang-2) and Vascular Endothelial Growth Factor-A (VEGF-A), associated with retinal diseases. Clinical trials demonstrated non-inferior vision improvements compared to traditional therapy, with a favorable safety profile.
Major companies in the retinal disorder treatment market are actively developing innovative products, including treatments for geographic atrophy, to expand their customer bases, boost sales, and increase revenue. Geographic atrophy treatments focus on symptom management, disease progression mitigation, and aiding individuals in coping with visual impairment. For instance, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, received FDA approval for IZERVAY. As a novel complement C5 inhibitor, IZERVAY is the sole approved treatment for geographic atrophy (GA) showing a statistically significant reduction (p< 0.01) in the rate of GA progression in two Phase 3 clinical trials. This distinction positions IZERVAY as an effective therapy for GA secondary to age-related macular degeneration (AMD).
In July 2023, Astellas Pharma Inc. acquired Iveric Bio Inc., a biopharmaceutical company based in the United States, for an undisclosed amount. This strategic acquisition is aimed at expanding Astellas' presence in ophthalmology, gaining access to innovative therapies for retinal diseases, and enhancing its position in the market for treating ophthalmologic conditions and vision loss.
Major companies operating in the retinal disorder treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Adverum Biotechnologies Inc., Kodiak Sciences Inc., Acucela Inc., IVERIC bio Inc., Oxurion NV, Graybug Vision Inc., Icon Bioscience Inc., Clearside Biomedical Inc., Aerpio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Ophthotech Corporation, Opthea Limited, PanOptica Inc., ThromboGenics NV.
North America was the largest region in the retinal disorder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinal disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The main types of retinal disorder treatment include macular degeneration, diabetic retinopathy, and others. Macular degeneration, often referred to as age-related macular degeneration (AMD), is a chronic eye condition primarily affecting the macula - the central area of the retina responsible for clear central vision. Treatment options are available in various dosage forms, including gels, eye solutions, capsules, tablets, eye drops, and ointments. These treatments are typically distributed through hospital pharmacies, online pharmacies, and retail pharmacies.
The retinal disorder treatment market research report is one of a series of new reports that provides retinal disorder treatment market statistics, including the retinal disorder treatment industry's global market size, regional shares, competitors with a retinal disorder treatment market share, detailed retinal disorder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinal disorder treatment industry. This retinal disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The retinal disorder treatment market includes revenues earned by entities by providing retinal detachment, laser treatment, genetic treatments, and photodynamic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Retinal Disorder Treatment Market Characteristics3. Retinal Disorder Treatment Market Trends and Strategies32. Global Retinal Disorder Treatment Market Competitive Benchmarking33. Global Retinal Disorder Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Retinal Disorder Treatment Market
4. Retinal Disorder Treatment Market - Macro Economic Scenario
5. Global Retinal Disorder Treatment Market Size and Growth
6. Retinal Disorder Treatment Market Segmentation
7. Retinal Disorder Treatment Market Regional and Country Analysis
8. Asia-Pacific Retinal Disorder Treatment Market
9. China Retinal Disorder Treatment Market
10. India Retinal Disorder Treatment Market
11. Japan Retinal Disorder Treatment Market
12. Australia Retinal Disorder Treatment Market
13. Indonesia Retinal Disorder Treatment Market
14. South Korea Retinal Disorder Treatment Market
15. Western Europe Retinal Disorder Treatment Market
16. UK Retinal Disorder Treatment Market
17. Germany Retinal Disorder Treatment Market
18. France Retinal Disorder Treatment Market
19. Italy Retinal Disorder Treatment Market
20. Spain Retinal Disorder Treatment Market
21. Eastern Europe Retinal Disorder Treatment Market
22. Russia Retinal Disorder Treatment Market
23. North America Retinal Disorder Treatment Market
24. USA Retinal Disorder Treatment Market
25. Canada Retinal Disorder Treatment Market
26. South America Retinal Disorder Treatment Market
27. Brazil Retinal Disorder Treatment Market
28. Middle East Retinal Disorder Treatment Market
29. Africa Retinal Disorder Treatment Market
30. Retinal Disorder Treatment Market Competitive Landscape and Company Profiles
31. Retinal Disorder Treatment Market Other Major and Innovative Companies
35. Retinal Disorder Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Retinal Disorder Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on retinal disorder treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for retinal disorder treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Type: Macular Degeneration; Diabetic Retinopathy; Other Types
2) By Dosage Form: Gels; Eye Solutions; Capsules and Tablets; Eye Drops; Ointments
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Regeneron Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Genentech Inc.
- Santen Pharmaceutical Co. Ltd.
- Apellis Pharmaceuticals Inc.
- Kubota Pharmaceutical Holdings Co. Ltd
- Alimera Sciences Inc.
- Ocular Therapeutix Inc.
- EyePoint Pharmaceuticals Inc.
- Adverum Biotechnologies Inc.
- Kodiak Sciences Inc.
- Acucela Inc.
- IVERIC bio Inc.
- Oxurion NV
- Graybug Vision Inc.
- Icon Bioscience Inc.
- Clearside Biomedical Inc.
- Aerpio Pharmaceuticals Inc.
- Neurotech Pharmaceuticals Inc.
- Ophthotech Corporation
- Opthea Limited
- PanOptica Inc.
- ThromboGenics NV
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | February 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 12.74 Billion |
Forecasted Market Value ( USD | $ 17.93 Billion |
Compound Annual Growth Rate | 8.9% |
Regions Covered | Global |
No. of Companies Mentioned | 29 |